PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan's 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio's website at investors.passa ...

EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that company management will participate in the following events at Chardan's 8th Annual Genetic Medicines Conference: Fireside chat on Monday, September 30, 2024, 2:30 PM - 3:00 PM ET with Brian Thomas, CEO and Founder, Dr. Sarah Noonberg, CMO, and Alan Brooks, SVP P ...

MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GENE"), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicagobased CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ h ...

BofA Securities has upgraded Fulcrum Therapeutics FULC ahead of the company's phase 3 losmapimod readout, expected by the end of October for Facioscapulohumeral muscular dystrophy (FSHD). FSHD is a rare genetic muscle disease affecting a child's facial muscles, shoulders, upper arms, and lower legs. These muscles weaken and shrink (atrophy). The analyst notes that although a previous pivotal study failed using the DUX4 expression endpoint, the company conducted a post-hoc analysis and designed a new study w ...

Initial data from largest international Parkinson's disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these individuals potential candidates to be included in gene-targeted trials The Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of Parkinson's disease (PD) to establish a better understanding of disease progression, diagnosis, and treatment for patients CAMBRIDGE, Mass. and ROSTOC ...

Transition to a capital light operating model; with lower cost operations Continued focus on the Company's core business of "EasyDNA" and "GeneType" Working capital funded by short term $800,000 secured loan (from lenders including Directors) Active Channel partners in the USA with geneType sales growth EasyDNA sales of $7m and growing The Company intends to fund working capital requirements with (i) a secured loan facility of $800,000; plus (ii) launching an Entitlement Offer. EasyDNA and AffinityDNA proje ...

Transition to a capital light operating model; with lower cost operations Continued focus on the Company's core business of "EasyDNA" and "GeneType" Working capital funded by short term $800,000 secured loan (from lenders including Directors) Active Channel partners in the USA with geneType sales growth EasyDNA sales of $7m and growing The Company intends to fund working capital requirements with (i) a secured loan facility of $800,000; plus (ii) launching an Entitlement Offer. EasyDNA and AffinityDNA proje ...

Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and consumer segments that include senior finance leadership roles with major ASX listed companies including Cochlear Limited, Aristocrat Leisure Limited, Coca-Cola Amatil Limited and Goodman Fielder Limited. More recently, in roles as an executive, interim or non-executive director he has been supporting emerging, technology-driven businesses scale, g ...

Forward Looking Statements MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and ...

Core Viewpoint - WiMi Hologram Cloud Inc. has announced a new blockchain consensus algorithm based on genetic algorithms, aimed at improving computational efficiency and overall performance in consortium blockchain networks [1][4]. Group 1: Blockchain Technology - The genetic algorithm is a stochastic search and optimization technique that enhances the consensus process by selecting the best nodes in a coalition blockchain network [2][3]. - This algorithm improves the efficiency of consensus, block generation, and computation by filtering consensus nodes based on their performance metrics [3][4]. - The optimization of the consensus mechanism is a complex and ongoing process, with expectations for more efficient algorithms to emerge in the future [4]. Group 2: Company Overview - WiMi Hologram Cloud, Inc. is a comprehensive technical solution provider specializing in holographic AR technologies, including automotive HUD software, 3D holographic pulse LiDAR, and holographic communication [5]. - The company focuses on various professional areas, offering services that encompass holographic AR applications, software development, and advertising technologies [5].